In a preclinical model, the blockage of CSF-1R signaling in glioma-bearing mice by using the anti-CSF-1R antibody Pexidartinib (PLX3397) resulted in a significantly reduced tumor infiltration of GAMs [112]. This evidence concerns the gene CSF1R and glioma.